Newly discovered heart molecule could lead to effective treatment for heart failure

August 10, 2014
Researchers led by a team at Indiana University School of Medicine have discovered a cardiac compound that could lead to new treatment for heart failure. Credit: Indiana University

Researchers have discovered a previously unknown cardiac molecule that could provide a key to treating, and preventing, heart failure.

The newly discovered molecule provides the heart with a tool to block a protein that orchestrates genetic disruptions when the heart is subjected to stress, such as .

When the research team, led by Ching-Pin Chang, M.D., Ph.D., associate professor of medicine at the Indiana University School of Medicine, restored levels of the newly discovered molecule in mice experiencing heart failure, the progression to heart failure was stopped. The research was published in the online edition of the journal Nature.

The newly discovered molecule is known as a long non-coding RNA. RNA's usual role is to carry instructions—the code—from the DNA in a cell's nucleus to the machinery in the cell that produces proteins necessary for cell activities. In recent years, scientists have discovered several types of RNA that are not involved in protein coding but act on their own. The role in the heart of long non-coding RNA has been unknown.

But the researchers determined that the newly discovered non-coding RNA, which they named Myheart—for myosin heavy-chain-associated RNA transcript—is responsible for controlling a protein called BRG1 (pronounced "berg-1"). In earlier research published in Nature in 2010, Dr. Chang and his colleagues discovered that BRG1 plays a crucial role in the development of the heart in the fetus.

But as the heart grows and needs to mature into its adult form, BRG1 is no longer needed, so very little of it is produced. That is, until the adult heart is subjected to significant stress such as high blood pressure or damage from a . Dr. Chang's previous research showed that in those conditions, BRG1 re-emerges and begins altering the heart's genetic activity, leading to heart failure. At the same time, production of Myheart is suppressed, so BRG1 can latch onto the DNA and alter the genetic material unchecked.

In the current Nature paper, the researchers reported that in mice with stress-induced high levels of BRG1, they were able to restore Myheart to normal levels using . Restoring Myheart levels blocked BRG1 actions and prevented heart failure, they said.

"I think of Myheart as a molecular crowbar that pries BRG1 off the genomic DNA and prevents it from manipulating ," said Dr. Chang, director of molecular and translational medicine at the Krannert Institute of Cardiology.

Although the results in mice would suggest testing Myheart against in humans, it is too large—by molecular standards—to be delivered as a drug, Dr. Chang said.

So he and his colleagues now are working to identify smaller portions of the Myheart molecule that are key to its ability to block BRG1. Such a subsection of the Myheart molecule could lead to a compound to test in human trials.

Explore further: A promising new approach for treating leukemia discovered

More information: A long noncoding RNA protects the heart from pathological hypertrophy, Nature, DOI: 10.1038/nature13596

Related Stories

A promising new approach for treating leukemia discovered

February 13, 2014

A group of researchers at the Institute for Research in Immunology and Cancer (IRIC) of Université de Montréal discovered a promising new approach to treating leukemia by disarming a gene that is responsible for tumor progression. ...

BRG1 mutations confer resistance to hormones in lung cancer

March 15, 2012

Retinoic acid (vitamin A) and steroids are hormones found in our body that protect against oxidative stress, reduce inflammation and are involved in cellular differentiation processes. One of the characteristics of tumours ...

Small RNAs in blood may reveal heart injury

August 1, 2014

(Medical Xpress)—Like clues to a crime, specific molecules in the body can hint at exposure to toxins, infectious agents or even trauma, and so help doctors determine whether and how to treat a patient. In recent years, ...

Recommended for you

Artificial beta cells

December 8, 2016

Researchers led by ETH Professor Martin Fussenegger at the Department of Biosystems Science and Engineering (D-BSSE) in Basel have produced artificial beta cells using a straightforward engineering approach.

Key regulator of bone development identified

December 8, 2016

Loss of a key protein leads to defects in skeletal development including reduced bone density and a shortening of the fingers and toes—a condition known as brachydactyly. The discovery was made by researchers at Penn State ...

Researchers question lifelong immunity to toxoplasmosis

December 8, 2016

Medical students are taught that once infected with Toxoplasma gondii—the "cat parasite"—then you're protected from reinfection for the rest of your life. This dogma should be questioned, argue researchers in an Opinion ...

TET proteins drive early neurogenesis

December 7, 2016

The fate of stem cells is determined by series of choices that sequentially narrow their available options until stem cells' offspring have found their station and purpose in the body. Their decisions are guided in part by ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.